What class of medication is Fanapt (iloperidone)?

Fanapt (Iloperidone) Medication Class

Fanapt (iloperidone) is an atypical second-generation antipsychotic medication belonging to the piperidinyl-benzisoxazole chemical class, with a primary mechanism of action as a combined dopamine D2 and serotonin 5-HT2A receptor antagonist. 1, 2

Chemical Classification and Mechanism

• Iloperidone is classified as a benzisoxazole derivative, sharing this chemical structure with risperidone 1, 3
• The drug's molecular formula is C24H27FN2O4 with a molecular weight of 426.48 1
• Its core mechanism involves D2/5-HT2A receptor antagonism, which is the defining characteristic of atypical antipsychotics 4, 5

Pharmacological Profile

• Beyond its primary D2 and 5-HT2A antagonism, iloperidone exhibits a multiple receptor binding profile affecting histamine, muscarinic, α1-adrenergic, and additional serotonin receptors 6, 3
• This broad receptor affinity creates a unique side effect profile that distinguishes it from other atypical antipsychotics 6
• The drug is highly protein-bound and undergoes extensive hepatic metabolism, primarily through CYP3A4 and CYP2D6 enzymes 6, 3

FDA Approval and Indications

• Iloperidone received FDA approval in May 2009 for the acute treatment of schizophrenia in adults 4, 5
• The drug has been studied in over 3,200 patients throughout its clinical development program 6, 5
• Asenapine (another atypical antipsychotic approved around the same time) has an additional indication for bipolar disorder, but iloperidone's approval is limited to schizophrenia 2

Clinical Context Within Antipsychotic Classes

• Iloperidone is categorized as a "second-generation" or "atypical" antipsychotic, distinguishing it from first-generation typical antipsychotics like haloperidol 2, 4
• Its efficacy appears similar to haloperidol, risperidone, and ziprasidone in treating schizophrenia 6
• The drug demonstrates minimal extrapyramidal side effects, weight gain, and prolactin elevation compared to many other antipsychotics 6, 5

Important Safety Considerations

• Iloperidone requires a cautious dosing and titration schedule at initiation due to potential orthostatic hypotension and dizziness 6
• Like other antipsychotics, iloperidone has been shown to prolong the QTc interval, which requires monitoring 6, 5
• Drug interactions through CYP3A4 and CYP2D6 pathways may influence its use in patients taking other medications 6

Unique Features

• Pharmacogenetic studies conducted during development identified genetic markers associated with increased response to iloperidone, suggesting potential for personalized medicine approaches 5
• A long-term 4-week injectable formulation was under development to assist with patient compliance 5